株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血小板減少症:パイプライン製品の分析

Thrombocytopenia - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232814
出版日 ページ情報 英文 163 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
血小板減少症:パイプライン製品の分析 Thrombocytopenia - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 163 Pages
概要

血小板減少症は、血小板数の異常な減少が特徴です。原因として、骨髄中の血小板の生産減少、脾臓または肝臓の血流中の血小板の破壊亢進などが挙げられます。口内・歯茎の出血、あざ、鼻血、発疹などの症状が見られます。治療は、止血または出血の予防として、血小板の輸血が行われます。

当レポートでは、血小板減少症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

血小板減少症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

血小板減少症:企業で開発中の治療薬

血小板減少症:大学/機関で研究中の治療薬

血小板減少症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

血小板減少症:企業で開発中の製品

血小板減少症:大学/機関で研究中の製品

血小板減少症の治療薬開発に従事している企業

  • 3SBio Inc.
  • Amarillo Biosciences, Inc.
  • Amgen Inc.
  • Baxalta Incorporated
  • Bayer AG
  • BioLineRx, Ltd.
  • Boehringer Ingelheim GmbH
  • Bolder Biotechnology, Inc.
  • Bristol-Myers Squibb Company
  • Cellerant Therapeutics, Inc.
  • エーザイ
  • Genosco
  • Hansa Medical AB
  • Immunomedics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Momenta Pharmaceuticals, Inc.
  • Myelo Therapeutics GmbH
  • Neumedicines Inc.
  • Novartis AG
  • Pfizer Inc.
  • PhytoHealth Corporation
  • Prophylix Pharma AS
  • Protalex, Inc.
  • Rigel Pharmaceuticals, Inc.
  • 塩野義製薬
  • STATegics, Inc.
  • UCB S.A.
  • ViroMed Co., Ltd.

血小板減少症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

血小板減少症:最近のパイプライン動向

血小板減少症:休止中のプロジェクト

血小板減少症:開発が中止された製品

血小板減少症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8676IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombocytopenia - Pipeline Review, H2 2016, provides an overview of the Thrombocytopenia (Hematological Disorders) pipeline landscape.

Thrombocytopenia is characterized by an abnormally low amount of platelets Low platelet levels occur due to less production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream or in the spleen or liver. Symptoms include bleeding in the mouth and gums, bruising, nosebleeds and rashes. Treatment includes transfusion of platelets to stop or prevent bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombocytopenia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thrombocytopenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thrombocytopenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 10, 6, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.Thrombocytopenia.

Thrombocytopenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombocytopenia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Thrombocytopenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thrombocytopenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thrombocytopenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thrombocytopenia (Hematological Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thrombocytopenia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thrombocytopenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thrombocytopenia Overview
  • Therapeutics Development
    • Pipeline Products for Thrombocytopenia - Overview
    • Pipeline Products for Thrombocytopenia - Comparative Analysis
  • Thrombocytopenia - Therapeutics under Development by Companies
  • Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes
  • Thrombocytopenia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Thrombocytopenia - Products under Development by Companies
  • Thrombocytopenia - Products under Investigation by Universities/Institutes
  • Thrombocytopenia - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • AkaRx Inc
    • Amarillo Biosciences, Inc.
    • Amgen Inc.
    • arGEN-X BV
    • BioLineRx, Ltd.
    • Biotest AG
    • Boehringer Ingelheim GmbH
    • Bolder Biotechnology, Inc.
    • Bristol-Myers Squibb Company
    • Cellerant Therapeutics, Inc.
    • Genosco
    • Hansa Medical AB
    • Immunomedics, Inc.
    • Intas Pharmaceuticals Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Merck & Co., Inc.
    • Momenta Pharmaceuticals, Inc.
    • Myelo Therapeutics GmbH
    • Neumedicines Inc.
    • Novartis AG
    • Pfizer Inc.
    • PhytoHealth Corporation
    • Prophylix Pharma AS
    • Protalex, Inc.
    • Rigel Pharmaceuticals, Inc.
    • Shionogi & Co., Ltd.
    • Shire Plc
    • STATegics, Inc.
    • UCB SA
    • ViroMed Co Ltd
  • Thrombocytopenia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibody for Autoimmune Disorders and Inflammation - Drug Profile
    • ARGX-113 - Drug Profile
    • avatrombopag - Drug Profile
    • BBT-059 - Drug Profile
    • BI-655064 - Drug Profile
    • BL-8040 - Drug Profile
    • BMS-986004 - Drug Profile
    • BT-595 - Drug Profile
    • CLT-009 - Drug Profile
    • eltrombopag olamine - Drug Profile
    • eltrombopag olamine - Drug Profile
    • fostamatinib disodium - Drug Profile
    • GL-2045 - Drug Profile
    • GSK-2285921 - Drug Profile
    • Hetrombopag Olamine - Drug Profile
    • interferon alfa - Drug Profile
    • lusutrombopag - Drug Profile
    • M-281 - Drug Profile
    • MK-8723 - Drug Profile
    • Monoclonal Antibody to Agonize Thrombopoietin Receptor for Thrombocytopenia - Drug Profile
    • Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile
    • Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile
    • Myelo-001 - Drug Profile
    • NMIL-121 - Drug Profile
    • Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile
    • PEG-VM501 - Drug Profile
    • PHN-013 - Drug Profile
    • PRTX-100 - Drug Profile
    • Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile
    • romiplostim - Drug Profile
    • romiplostim biosimilar - Drug Profile
    • SHP-652 - Drug Profile
    • SKIO-703 - Drug Profile
    • Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile
    • Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile
    • STST-4 - Drug Profile
    • thrombopoietin - Drug Profile
    • Tromplate - Drug Profile
    • TXA-302 - Drug Profile
    • UCB-7665 - Drug Profile
    • veltuzumab - Drug Profile
  • Thrombocytopenia - Dormant Projects
  • Thrombocytopenia - Discontinued Products
  • Thrombocytopenia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thrombocytopenia, H2 2016
  • Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Thrombocytopenia - Pipeline by 3SBio Inc., H2 2016
  • Thrombocytopenia - Pipeline by AkaRx Inc, H2 2016
  • Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H2 2016
  • Thrombocytopenia - Pipeline by Amgen Inc., H2 2016
  • Thrombocytopenia - Pipeline by arGEN-X BV, H2 2016
  • Thrombocytopenia - Pipeline by BioLineRx, Ltd., H2 2016
  • Thrombocytopenia - Pipeline by Biotest AG, H2 2016
  • Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H2 2016
  • Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016
  • Thrombocytopenia - Pipeline by Genosco, H2 2016
  • Thrombocytopenia - Pipeline by Hansa Medical AB, H2 2016
  • Thrombocytopenia - Pipeline by Immunomedics, Inc., H2 2016
  • Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Thrombocytopenia - Pipeline by Merck & Co., Inc., H2 2016
  • Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H2 2016
  • Thrombocytopenia - Pipeline by Neumedicines Inc., H2 2016
  • Thrombocytopenia - Pipeline by Novartis AG, H2 2016
  • Thrombocytopenia - Pipeline by Pfizer Inc., H2 2016
  • Thrombocytopenia - Pipeline by PhytoHealth Corporation, H2 2016
  • Thrombocytopenia - Pipeline by Prophylix Pharma AS, H2 2016
  • Thrombocytopenia - Pipeline by Protalex, Inc., H2 2016
  • Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
  • Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Thrombocytopenia - Pipeline by Shire Plc, H2 2016
  • Thrombocytopenia - Pipeline by STATegics, Inc., H2 2016
  • Thrombocytopenia - Pipeline by UCB SA, H2 2016
  • Thrombocytopenia - Pipeline by ViroMed Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Thrombocytopenia - Dormant Projects, H2 2016
  • Thrombocytopenia - Dormant Projects (Contd..1), H2 2016
  • Thrombocytopenia - Dormant Projects (Contd..2), H2 2016
  • Thrombocytopenia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Thrombocytopenia, H2 2016
  • Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top